MXPA03000966A - Agentes antidiabeticos. - Google Patents
Agentes antidiabeticos.Info
- Publication number
- MXPA03000966A MXPA03000966A MXPA03000966A MXPA03000966A MXPA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A MX PA03000966 A MXPA03000966 A MX PA03000966A
- Authority
- MX
- Mexico
- Prior art keywords
- antidiabetic agents
- antidiabetic
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36091302P | 2002-02-28 | 2002-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03000966A true MXPA03000966A (es) | 2003-09-04 |
Family
ID=27734776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03000966A MXPA03000966A (es) | 2002-02-28 | 2003-01-31 | Agentes antidiabeticos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6821977B2 (es) |
| EP (1) | EP1340500A1 (es) |
| JP (1) | JP2004002311A (es) |
| AU (1) | AU2003206028A1 (es) |
| BR (1) | BR0300314A (es) |
| CA (1) | CA2419685A1 (es) |
| MX (1) | MXPA03000966A (es) |
| WO (1) | WO2003072570A1 (es) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158192A0 (en) * | 2001-05-04 | 2004-03-28 | Pfizer Prod Inc | Method of preventing type 2 diabetes with aerosolized insulin |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| AU2003274462A1 (en) | 2002-11-07 | 2004-06-07 | Pfizer Products Inc. | N-(indole-2-carbonyl) amides as anti-diabetic agents |
| CN1964630A (zh) | 2003-02-13 | 2007-05-16 | 耶希瓦大学艾伯塔·爱恩斯坦医学院 | 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生 |
| EP1644335A4 (en) | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS |
| WO2006055462A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
| EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2006126695A1 (ja) * | 2005-05-23 | 2006-11-30 | Japan Tobacco Inc. | ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬 |
| US20080076742A1 (en) * | 2005-10-31 | 2008-03-27 | Wisconsin Alumni Research Foundation | Methods and compositions for treating diseases associated with neovascualrization |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| WO2008062739A1 (fr) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles et leur utilisation en tant que médicaments |
| US8637575B2 (en) | 2008-06-05 | 2014-01-28 | Novotyr Therapeutics Ltd. | Modulators of protein kinase signaling |
| US10155168B2 (en) | 2012-05-08 | 2018-12-18 | Snap Inc. | System and method for adaptable avatars |
| EP3021944B1 (en) | 2013-07-14 | 2018-12-19 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases |
| CN112494653A (zh) | 2015-02-05 | 2021-03-16 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| US10339365B2 (en) | 2016-03-31 | 2019-07-02 | Snap Inc. | Automated avatar generation |
| EP3535242B1 (en) | 2016-10-20 | 2024-01-24 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Dna primase and gyrase inhibitors |
| US10432559B2 (en) | 2016-10-24 | 2019-10-01 | Snap Inc. | Generating and displaying customized avatars in electronic messages |
| US10593116B2 (en) | 2016-10-24 | 2020-03-17 | Snap Inc. | Augmented reality object manipulation |
| US10242503B2 (en) | 2017-01-09 | 2019-03-26 | Snap Inc. | Surface aware lens |
| US10242477B1 (en) | 2017-01-16 | 2019-03-26 | Snap Inc. | Coded vision system |
| KR102449545B1 (ko) | 2017-04-27 | 2022-10-04 | 스냅 인코포레이티드 | 지리공간적 활동 메트릭들을 표시하는 지도-기반 그래픽 사용자 인터페이스 |
| US11122094B2 (en) | 2017-07-28 | 2021-09-14 | Snap Inc. | Software application manager for messaging applications |
| US10586368B2 (en) | 2017-10-26 | 2020-03-10 | Snap Inc. | Joint audio-video facial animation system |
| US11460974B1 (en) | 2017-11-28 | 2022-10-04 | Snap Inc. | Content discovery refresh |
| US10979752B1 (en) | 2018-02-28 | 2021-04-13 | Snap Inc. | Generating media content items based on location information |
| US10726603B1 (en) | 2018-02-28 | 2020-07-28 | Snap Inc. | Animated expressive icon |
| US11310176B2 (en) | 2018-04-13 | 2022-04-19 | Snap Inc. | Content suggestion system |
| US11030813B2 (en) | 2018-08-30 | 2021-06-08 | Snap Inc. | Video clip object tracking |
| US10895964B1 (en) | 2018-09-25 | 2021-01-19 | Snap Inc. | Interface to display shared user groups |
| US10698583B2 (en) | 2018-09-28 | 2020-06-30 | Snap Inc. | Collaborative achievement interface |
| US10904181B2 (en) | 2018-09-28 | 2021-01-26 | Snap Inc. | Generating customized graphics having reactions to electronic message content |
| US11189070B2 (en) | 2018-09-28 | 2021-11-30 | Snap Inc. | System and method of generating targeted user lists using customizable avatar characteristics |
| US11245658B2 (en) | 2018-09-28 | 2022-02-08 | Snap Inc. | System and method of generating private notifications between users in a communication session |
| US10872451B2 (en) | 2018-10-31 | 2020-12-22 | Snap Inc. | 3D avatar rendering |
| US11176737B2 (en) | 2018-11-27 | 2021-11-16 | Snap Inc. | Textured mesh building |
| US11199957B1 (en) | 2018-11-30 | 2021-12-14 | Snap Inc. | Generating customized avatars based on location information |
| US10861170B1 (en) | 2018-11-30 | 2020-12-08 | Snap Inc. | Efficient human pose tracking in videos |
| US11516173B1 (en) | 2018-12-26 | 2022-11-29 | Snap Inc. | Message composition interface |
| US11294936B1 (en) | 2019-01-30 | 2022-04-05 | Snap Inc. | Adaptive spatial density based clustering |
| US10936066B1 (en) | 2019-02-13 | 2021-03-02 | Snap Inc. | Sleep detection in a location sharing system |
| US10852918B1 (en) | 2019-03-08 | 2020-12-01 | Snap Inc. | Contextual information in chat |
| US11188190B2 (en) | 2019-06-28 | 2021-11-30 | Snap Inc. | Generating animation overlays in a communication session |
| US11676199B2 (en) | 2019-06-28 | 2023-06-13 | Snap Inc. | Generating customizable avatar outfits |
| US11307747B2 (en) | 2019-07-11 | 2022-04-19 | Snap Inc. | Edge gesture interface with smart interactions |
| US11455081B2 (en) | 2019-08-05 | 2022-09-27 | Snap Inc. | Message thread prioritization interface |
| US11320969B2 (en) | 2019-09-16 | 2022-05-03 | Snap Inc. | Messaging system with battery level sharing |
| US11080917B2 (en) | 2019-09-30 | 2021-08-03 | Snap Inc. | Dynamic parameterized user avatar stories |
| US11218838B2 (en) | 2019-10-31 | 2022-01-04 | Snap Inc. | Focused map-based context information surfacing |
| US11063891B2 (en) | 2019-12-03 | 2021-07-13 | Snap Inc. | Personalized avatar notification |
| US11128586B2 (en) | 2019-12-09 | 2021-09-21 | Snap Inc. | Context sensitive avatar captions |
| US11227442B1 (en) | 2019-12-19 | 2022-01-18 | Snap Inc. | 3D captions with semantic graphical elements |
| US11263817B1 (en) | 2019-12-19 | 2022-03-01 | Snap Inc. | 3D captions with face tracking |
| US11169658B2 (en) | 2019-12-31 | 2021-11-09 | Snap Inc. | Combined map icon with action indicator |
| US11356720B2 (en) | 2020-01-30 | 2022-06-07 | Snap Inc. | Video generation system to render frames on demand |
| US11036781B1 (en) | 2020-01-30 | 2021-06-15 | Snap Inc. | Video generation system to render frames on demand using a fleet of servers |
| US11217020B2 (en) | 2020-03-16 | 2022-01-04 | Snap Inc. | 3D cutout image modification |
| US11625873B2 (en) | 2020-03-30 | 2023-04-11 | Snap Inc. | Personalized media overlay recommendation |
| US11818286B2 (en) | 2020-03-30 | 2023-11-14 | Snap Inc. | Avatar recommendation and reply |
| US11580682B1 (en) | 2020-06-30 | 2023-02-14 | Snap Inc. | Messaging system with augmented reality makeup |
| US11360733B2 (en) | 2020-09-10 | 2022-06-14 | Snap Inc. | Colocated shared augmented reality without shared backend |
| US11452939B2 (en) | 2020-09-21 | 2022-09-27 | Snap Inc. | Graphical marker generation system for synchronizing users |
| US11615592B2 (en) | 2020-10-27 | 2023-03-28 | Snap Inc. | Side-by-side character animation from realtime 3D body motion capture |
| US11544885B2 (en) | 2021-03-19 | 2023-01-03 | Snap Inc. | Augmented reality experience based on physical items |
| US11636654B2 (en) | 2021-05-19 | 2023-04-25 | Snap Inc. | AR-based connected portal shopping |
| US11673054B2 (en) | 2021-09-07 | 2023-06-13 | Snap Inc. | Controlling AR games on fashion items |
| US11663792B2 (en) | 2021-09-08 | 2023-05-30 | Snap Inc. | Body fitted accessory with physics simulation |
| US11734866B2 (en) | 2021-09-13 | 2023-08-22 | Snap Inc. | Controlling interactive fashion based on voice |
| US11636662B2 (en) | 2021-09-30 | 2023-04-25 | Snap Inc. | Body normal network light and rendering control |
| US11651572B2 (en) | 2021-10-11 | 2023-05-16 | Snap Inc. | Light and rendering of garments |
| US11790614B2 (en) | 2021-10-11 | 2023-10-17 | Snap Inc. | Inferring intent from pose and speech input |
| US11823346B2 (en) | 2022-01-17 | 2023-11-21 | Snap Inc. | AR body part tracking system |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1114834A (zh) * | 1993-09-28 | 1996-01-10 | 大塚制药株式会社 | 抗糖尿病剂 |
| ATE206702T1 (de) * | 1995-06-06 | 2001-10-15 | Pfizer | Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren |
| ES2161291T3 (es) * | 1995-06-06 | 2001-12-01 | Pfizer | N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa. |
| JP2003506358A (ja) * | 1999-07-29 | 2003-02-18 | エギシュ ヂョヂセルヂャール エルテー | イソキノリン誘導体、該誘導体を含有する医薬組成物及び活性物質の製法 |
| AU7315700A (en) * | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| DE10115994A1 (de) * | 2001-03-30 | 2002-10-10 | Wella Ag | (p-Amino-hydroxyphenyl)acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel |
| WO2002096858A1 (en) * | 2001-05-31 | 2002-12-05 | Bristol-Myers Squibb Company | Cinnamide derivatives as kcnq potassium channel modulators |
| DE20110355U1 (de) * | 2001-06-22 | 2001-08-30 | Wella Ag, 64295 Darmstadt | (Dihydroxyphenyl)-acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel |
-
2003
- 2003-01-31 MX MXPA03000966A patent/MXPA03000966A/es unknown
- 2003-02-14 EP EP03250913A patent/EP1340500A1/en not_active Withdrawn
- 2003-02-17 WO PCT/IB2003/000628 patent/WO2003072570A1/en not_active Application Discontinuation
- 2003-02-17 AU AU2003206028A patent/AU2003206028A1/en not_active Abandoned
- 2003-02-18 JP JP2003039158A patent/JP2004002311A/ja not_active Withdrawn
- 2003-02-19 US US10/368,916 patent/US6821977B2/en not_active Expired - Fee Related
- 2003-02-24 CA CA002419685A patent/CA2419685A1/en not_active Abandoned
- 2003-02-26 BR BR0300314-0A patent/BR0300314A/pt not_active IP Right Cessation
-
2004
- 2004-08-19 US US10/923,537 patent/US20050020661A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1340500A1 (en) | 2003-09-03 |
| CA2419685A1 (en) | 2003-08-28 |
| JP2004002311A (ja) | 2004-01-08 |
| BR0300314A (pt) | 2004-09-08 |
| WO2003072570A1 (en) | 2003-09-04 |
| US20030199553A1 (en) | 2003-10-23 |
| US20050020661A1 (en) | 2005-01-27 |
| US6821977B2 (en) | 2004-11-23 |
| AU2003206028A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03000966A (es) | Agentes antidiabeticos. | |
| SI1555267T1 (sl) | 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI | |
| DE60302150D1 (en) | N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren | |
| AU2003286867A8 (en) | E.x.o. rimwear | |
| IL159152A0 (en) | 3-fluoro-pyrrolidines as antidiabetic agents | |
| HK1078568A1 (en) | 2-(2,6-dichlorophenyl)-diarylimidazoles | |
| ZA200307420B (en) | Point chisel. | |
| MXPA03007695A (es) | Placa de teclas. | |
| AU2003290818A8 (en) | Topoisomerase-targeting agents | |
| AU2003215804A1 (en) | Antidiabetic agents | |
| SG116498A1 (en) | Cleaning tool. | |
| AU2003215803A1 (en) | Antidiabetic agents | |
| GB0202011D0 (en) | The Fucker | |
| GB0218515D0 (en) | S.d.s. | |
| EG23241A (en) | Beshob. | |
| ZA200408169B (en) | Imidazolinylmethyl aralkylsulfonamides. | |
| MXPA02003350A (es) | Calentador-tanque-termo-solar. | |
| MXPA02001688A (es) | Marco facil. | |
| GB0209707D0 (en) | Bidfor100.com | |
| ZA200207924B (en) | Combination tool. | |
| GB0215256D0 (en) | I.t | |
| GB0212492D0 (en) | D.I.Y. workvest | |
| GB0204798D0 (en) | Cycostatic agents | |
| ZA200307195B (en) | Mechanical tools. | |
| ZA200304737B (en) | A combination. |